Wepe rformed a retrospective study of47pa tients to ascertain the ability of combinedp ositron-emission tomography andcomputed tomograp hy (PETICT) to localize recurrent head and neck cancel: When clinically warranted, biopsies were pe rformed in an attempt to obtain p athologic confirmation of the PETICTfindings. Of the 47 patients, 33 exhibited PETICT findi ngs consistent with recurrent cancer. Of the 33 patients, 25 underwent either biopsy or surgical excision ofdisease in an attemp t to obtain a path ologic confirmation. Biopsy analysis confir med the PETICTfi ndings in 22 ofthese p atients; in the remaining 3 patients, p athologic fi ndings were inconsistent with the PETICT diagnosis. Based on the subset of25 patients who underwent p athologic testing, the sensitivity ofcombined PETICT was 95% and the specificity was 60%. We conclude that combined PE TICT imaging is a valuable tool f or localizing tumor recurrence in p atients with head and neck cancer.
Introduction
The diagnosis of recurrent head and neck cancer is a challenge in patients treated with radi ation therapy, surgery, or both. Postsurgical anatomic changes and inflammation associated with radiation limit the diagnostic accuracy of trad itional imaging modalities such as computed tomo graphy (CT) and magnetic resonance imaging (MRI).I Altern atively, the use of panend oscopy with biopsy of irradiated tissues in patient s with a presumed recurrence may promote radionecrosis; furtherm ore, many patients without recurrence would be exposed to additional surgical and anesthetic risks. An imaging mod ality that would help localize recurrence and guide the pathologic diagnosi s of cancer in these patients would be beneficial.
Positron-emission tomography (PET) has been shown to be effective in detecting a variety ofcancers in different areas of the head and neck.P Accelerated glucos e metabolism, reflected by a focally increased uptake of[ 18F]2-fluoro-2deoxyglucose (FDG), is highly correlated with malignancy. Howev er, the limited spatial resolution and the lack of anatomic detail associated with PET often make it difficult to precisely localize a tumor, given the variable degree of physiologic FDG uptak e that occurs in the head and neck. This inability to preci sely localize a tumor can confound diagnosis, stag ing, and treatment plannin g.
A protot ype combination PETICT scanner was developed at the University of Pittsburgh to localize neoplastic lesions throughout the body. -' Initial studies demonstrated that PETICT was more effective than PET alone in this regard. In this article, we describ e our early experience with combined PETIC T in patients with recurrent head and neck cancer.
Patients and methods
We examined the reco rds of 47 patients-29 men and 18 women, aged 51 to 102 years (mean: 64. For more information Circle 103 on Reader Service Card same assembly and offset axially by 60 em. A moving bed allowed for dual -modal ity imag ing with an ax ial extent of 100 em. Data were acquired sequentially ; the CT images were obtained first. Detailed technical information on this equipment can be found in previous pub licatio ns.' > Patients were injected with approximately 260 MBq of FOG. After an interval of approximately 60 minutes to allow for adeq uate FOG uptake, patients were posi tioned in the scanner. A scout CT was performed to determine the axial range of the image . A helical CT of the neck through the chest was performed duri ng shallow breathing. Th e total CT scan ning tim e was approximately 5 minutes . Immediately foll owing CT, PET data were acquired ( 10 min per bed posi tion). Th e total scan time was approx imately 45 minutes.
Image analys is. Eac h image was reviewed by 2 sen ior radiologists, I of whom was board-certified in nucl ear medicine. Lesions were visually characterized according to' their location and the likelihood that they were ma lignant, based on FOG uptake. Imag ing findings were retrospectively compared with clinica l information, including CT reports contained in the pat ient records when available.
Surg ery. Patients with positi ve findi ngs on combined PET/CT were eva luated for surgery by senior staff otolaryngologists. Surgical specimens were sent for routine pathologic processi ng, and senior staff pat ho logists evalua ted and diagnosed eac h specimen. Patien ts with negative findings on PET/CT were followed clinically by staff oto lary ngo logists,
Results
Of the '47 patie nts, 29 had undergone a previous surg ical resection of head and neck cancer with or without chemora diation, and 18 had und ergone chemoradiatio n only. A total of 31 patients had biopsy-proven squ amous cell carci noma of the head and neck; the rem aining 16 had various other typ es of tumors.
Of the 47 patien ts, 33 exhibited PET/C T findings consistent with ca ncer. Of this group, 25 und erwent either biopsy or surgical excision of the tumor to obtain material for a pathologic diagnosis; the remai ning 8 pat ients were referred to the onco logy un it for treatment without patho logic confirmation. Three of these 8 refused furt her biopsies or surgery, and pathologic testing priorto medical treatment was not pursued in the other 5. The 14 patients whose imaging resu lts were negative were followed with routine physical exam inations and repeat PET/CT evaluations every 3 to 6 months.
In the 25 patients who underwent pathologic test ing, the average length of time between the orig inal surgical removal of disease and the PET/CT study was 22 mon ths (± I0). In this gro up, patho logy confirmed the PET/CT findings in 22 patient s. Th ere were 19 true positives and 3 true negatives (tab le). Of the 3 patien ts whose pathologic findings were inconsistent with PET/CT, there were 2 false 106 positives and I false negative . Therefore, the sensiti vity of PET/CT was 95%, the specificity was 60%, and the positive predictive value (PPY) was 90%.
The location of recurrence varied; 19 of the 25 patients (76%) demonstrated loca l recurrence, 10 (40%) had lymphatic recurrence, and 3 ( 12%) deve loped distant metastatic diseas e (table) .
On ly a few patients underwent concurrent radiologic exa minations by other moda lities (figures I, 2, and 3) and, therefore, a definitive direct comparison of PET/CT with CT alone and w ith MRI could not be addressed in this study.
Eightee n of the 25 patients (72%) had squamo us cell carcinoma. The sens itivity and specifici ty of PET/CT in patients with recurre nt squamous cell carcin oma were 94 and 50%, respectively, and the PPY was 94%.The sensitivity and spec ificity of PET/CT in the remai ning 7 patients were 100 and 67% res pect ively, and the PPY was 71%.
Discussion
Our data indicate that combined PET/CT is a useful tool for identifying and precisely localizing recurrent tumors in the head and neck . This precise anatom ic localization may allow for targe ted surgical excision and/or radiot herapy (brachytherap y). Furthermore, some patients with advanced disease may be referred directly for chemotherapy based on PET/CT resul ts and therefore woul d avo id the morbidity associated with surgery.
In our study, PET/CTyielded an overa ll sens itivity of95% and a specifici ty of60% for ident ifying recurre nt disease in the head and neck in patients undergoing patho logic testing for confirmatio n. Th e low spec ificity is likely attr ibutable to the fact that patie nts with negative imag ing find ings did not undergo test ing for pathologic confirmation. Neverth eless, the sensitivity and specificity we found are in close agree ment with those of previous stud ies of PET alone in the detection of head and neck cancers.v' Another important role of PET/CT may be the identificatio n of recurre nt disease in pos toperative and postirradiated tissues. Altered tissue planes , scarri ng, and radiation-induced necrosis and edema limit the usefulness oftraditional imaging techniques. Moreover, physical exami nation and conventional imagi ng techniques have been limited , as wel l.
In previous studies, PET alon e identified rec urrences in posttreatment necks with 100% accuracy, whereas the accuracy ofCT and physical examination was only 53 and 63%, respective ly,"In 1994, Greven ... However, it is well kno wn that a majo r limitation ofPET alone is its inability to localiz e the precise anatomic site of recurrence. Studies of retrospective registration of PET and CT or PET and MRI data sho wed that the avail abil ity of both anatomic and func tional information allo wed for the identification of more tumor sites and tumor marg ins than did conventional imag ing mod alities ." Although we did not directly compare the use of PET/CT with either CT alone or with MRI, other authors have .v' They found that PET/CT can be useful in evaluating patients whos e CT and/or MRI results are equivocal.
The timing ofPET following radiotherapy, and possibly following surgery, can affect its utility in tumor surveil-Volume 84 , Number 2 lance . In 1997, Keyes et al reported that PET yielded a high false-negative rate of 17% (7/4 1)at 1month following radiotherapy; at 4 and 12 months, however, there we re no false negati ves .II Even so, early PET is still superior to both physical examination and conve ntional imagi ng in this patient population. " PET/CT is not without its own limit ations . The PET component is limited by its poor spatia l resolution. Mo reover, PET is associated with a low sensitivity for tumors smaller than 1 em , wh ich can hinder the identification of microdeposits of'tumor.P:" :" Limited resolution and high background counts in secretions may limit the detection of small lesions of the tongue base , tonsils, and salivary Visit US at www.smelltest.com Z IMM ER, SNYDER MAN, FUKUI, BLODGETT, MCCO OK, TOW NSE ND , MELTZ ER glands. Newer genera tions of PET/CT sca nners and the use of scannin g age nts that are not secreted in saliva may further improve the detection rate of cancer in the head and neck.
Our study was limited by an inherent referral bias, as only patients with a clinical suspicion with or without CT and/or MRI we re referred for PET/CT. Likewi se, our study was limited by an eva luation bias, as patients with negative PET/CT scans and a low index ofsuspic ion did not undergo testing for pathologic confirmation, which precl uded us from interpreting negative PET/CT studies. Prospe ctive, randomized studies are warranted to comp are the efficacy of PET/CT with PET alone and CT alone.
'In conclusion, our results indicate that combined PET/CT is a valuable tool for the survei llance of recurrent and/or residual head and neck cancer following surgery and/o r chemoradiation. The information it provides can allow for the early detection of disease that is not evident on traditional imaging modalities, and it can allow for a greater chance at cure or palli ation with less surgica l morbidi ty.
